Searchable abstracts of presentations at key conferences in endocrinology

ea0081oc8.1 | Oral Communications 8: Calcium and Bone | ECE2022

Effectiveness of anti-resorptive drugs on risk of vertebral fractures in women receiving aromatase inhibitors: a prospective study in real-life clinical practice

Mazziotti Gherardo , Vena Walter , Pigni Stella , Carrone Flaminia , Pedersini Rebecca , Cosentini Deborah , Torrisi Rosalba , Birtolo Maria Francesca , Maida Giulia , Berruti Alfredo , Lania Andrea

Bone loss is a frequent complication of aromatase inhibitors (AIs) therapy in women with breast cancer. Bone-active drugs are effective in protecting the skeleton from detrimental actions of AIs. However, bone mineral density (BMD) was the primary end-point in most of published studies, whereas data on fractures were scant and mainly limited to denosumab. In this prospective study, we investigated the effects of denosumab, oral bisphosphonates and intravenous zoledronate on ri...

ea0081oc2.6 | Oral Communications 2: Adrenal and Cardiovascular Endocrinology 1 | ECE2022

Activity of abiraterone acetate in the management of cushing syndrome associated to advanced adrenocortical carcinoma: results of the ABACUS trial

Puglisi Soraya , Cosentini Deborah , Grisanti Salvatore , Basile Vittoria , Lagana Marta , Ferarri VittorioDomenico , Abate Andrea , Calabrese Anna , Rossini Elisa , Perotti Paola , Saba Laura , Pia Anna , Sigala Sandra , Berruti Alfredo , Terzolo Massimo

Background: More than 50% of adrenocortical carcinomas (ACC) in adults are associated with cortisol excess that makes tumor management challenging and has a negative impact on patient outcome. Abiraterone acetate (AA) is an irreversible inhibitor of the 17α-hydroxylase/C17, 20-lyase (CYP17 enzyme) that is used in patients with prostate cancer, in whom it leads to suppression of cortisol and androgens. The aim of this study was to assess the activity of AA to control corti...

ea0081p305 | Calcium and Bone | ECE2022

Reliability of who fracture risk assessment tool (frax) and bone mineral density in predicting fractures in cancer patients under hormone deprivation therapies: a real-world clinical study

Vena Walter , Piccini Sara , Pedersini Rebecca , Carrone Flaminia , Cosentini Deborah , Zucali Paolo , Torrisi Rosalba , Brunetti Alessandro , Pigni Stella , Maroldi Roberto , Balzarini Luca , Lania Andrea Gerardo , Berruti Alfredo , Berruti Gherardo

Background: Skeletal fragility is an important clinical issue in women with early-stage breast cancer and men with non-metastatic prostate cancer under hormonal hormone deprivation therapies (HDTs). Vertebral fractures (VFs) have been reported in a remarkable number of subjects exposed to HDT especially when the diagnosis of fractures is performed by a radiological and morphometric approach. Notably, prediction of fractures in this clinical setting is a challenge and determina...

ea0070oc1.6 | Adrenal and Cardiovascular Endocrinology | ECE2020

Modified GRAS score for prognostic classification of adrenocortical carcinoma: an ENSAT multicentre study

Elhassan Yasir , Altieri Barbara , Berhane Sarah , Cook Harriet , Bertherat Jerome , Fragoso Maria , Kastelan Darko , Terzolo Massimo , Calabrese Anna , Berruti Alfredo , Cosentini Deborah , Laganà Marta , Loli Paola , Baudin Eric , Haak Harm , Canu Letizia , Haissaguerre Magalie , Kimpel Otilia , Deeks Jon , Arlt Wiebke , Libé Rossella , Fassnacht Martin , Ronchi Cristina

Background: Adrenocortical carcinoma (ACC) has an aggressive but heterogenous behaviour. ENSAT stage and Ki67 proliferation index are used to predict clinical outcome but are limited in distinguishing patients with best outcome. We aimed to validate the prognostic role of clinical and histopathological parameters alone or combined by applying a previously proposed points-based score (mGRAS, Lippert JCEM 2018) to a large multicentre cohort of ACC patients.<p class="abstext"...